Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H28N2O3 |
| Molecular Weight | 368.4693 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)C1=CC=C(OCC(O)CN2CCN(CC2)C3=CC=CC=C3)C=C1
InChI
InChIKey=ZQPXSRTZFYHSFB-UHFFFAOYSA-N
InChI=1S/C22H28N2O3/c1-2-22(26)18-8-10-21(11-9-18)27-17-20(25)16-23-12-14-24(15-13-23)19-6-4-3-5-7-19/h3-11,20,25H,2,12-17H2,1H3
| Molecular Formula | C22H28N2O3 |
| Molecular Weight | 368.4693 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:29:11 UTC 2023
by
admin
on
Sat Dec 16 11:29:11 UTC 2023
|
| Record UNII |
R5YPG9LA47
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CENTPROPAZINE
Created by
admin on Sat Dec 16 11:29:11 UTC 2023 , Edited by admin on Sat Dec 16 11:29:11 UTC 2023
|
PRIMARY | CAS No. 34675-77-9; Chemical Name: Centpropazine | ||
|
91315-34-3
Created by
admin on Sat Dec 16 11:29:11 UTC 2023 , Edited by admin on Sat Dec 16 11:29:11 UTC 2023
|
PRIMARY | |||
|
DTXSID00919825
Created by
admin on Sat Dec 16 11:29:11 UTC 2023 , Edited by admin on Sat Dec 16 11:29:11 UTC 2023
|
PRIMARY | |||
|
118176
Created by
admin on Sat Dec 16 11:29:11 UTC 2023 , Edited by admin on Sat Dec 16 11:29:11 UTC 2023
|
PRIMARY | |||
|
R5YPG9LA47
Created by
admin on Sat Dec 16 11:29:11 UTC 2023 , Edited by admin on Sat Dec 16 11:29:11 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Single oral doses of 10 to 160 mg centpropazine, a new antidepressant (synthesized by CDRI, Lucknow, India) were administered to groups of 4-5 male volunteers, each dose being interspersed with placebo in a double blind, non-crossover study by random distribution. The drug was well tolerated. Drowsiness, heaviness, weakness and/or headache were reported only at doses of 120 mg and above. No adverse effect was noted in various laboratory tests, ECG or vital parameters.
|
||
|
ACTIVE MOIETY |
Centpropazine is a new antidepressant with minimal anticholinergic effects in preclinical animal models. In this study centpropazine has been compared with imipramine in a double blind randomized multicentric study. A total of 159 patients of major depressive disorder (79 in centpropazine group and 80 in imipramine group) from four centres were included in this trial. Each patient was randomised to receive either centpropazine in a dose of 40 to 120 mg per day or imipramine in a dose of 50 to 150 mg per day for a period of six weeks. The antidepressant efficacy of centpropazine was comparable to imipramine but anticholinergic side effects were four times less than imipramine.
|
